{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T16:39:08Z","timestamp":1794242348289,"version":"4.9.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,20]],"date-time":"2021-01-20T00:00:00Z","timestamp":1611100800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013840","name":"Biocenter Finland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013840","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015735","name":"Helsinki Institute of Life Science, Helsingin Yliopisto","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001858","name":"VINNOVA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002341","name":"Academy of Finland","doi-asserted-by":"publisher","award":["278741"],"award-info":[{"award-number":["278741"]}],"id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002341","name":"Academy of Finland","doi-asserted-by":"publisher","award":["333583"],"award-info":[{"award-number":["333583"]}],"id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006306","name":"Sigrid Jus\u00e9liuksen S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","award":["9V068"],"award-info":[{"award-number":["9V068"]}],"id":[{"id":"10.13039\/501100006306","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006383","name":"Sy\u00f6p\u00e4j\u00e4rjest\u00f6t","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006383","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.tranon.2021.101027","type":"journal-article","created":{"date-parts":[[2021,1,30]],"date-time":"2021-01-30T08:30:59Z","timestamp":1611995459000},"page":"101027","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["STRN-ALK rearranged pediatric malignant peritoneal mesothelioma \u2013 Functional testing of 527 cancer drugs in patient-derived cancer cells"],"prefix":"10.1016","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7797-188X","authenticated-orcid":false,"given":"Astrid","family":"Murum\u00e4gi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Ungureanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1627-9571","authenticated-orcid":false,"given":"Mariliina","family":"Arjama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"B\u00fctzow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jouko","family":"Lohi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannu","family":"Sariola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jukka","family":"Kanerva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3796-0991","authenticated-orcid":false,"given":"Minna","family":"Koskenvuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3231-0332","authenticated-orcid":false,"given":"Olli","family":"Kallioniemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.tranon.2021.101027_bib0001","first-page":"2020","article-title":"Anaplastic lymphoma kinase fusions: Roles in cancer and therapeutic perspectives","volume":"17","author":"Cao","year":"2019","journal-title":"Oncol Lett"},{"issue":"8","key":"10.1016\/j.tranon.2021.101027_bib0002","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11081074","article-title":"The transcriptional roles of ALK fusion proteins in tumorigenesis","volume":"11","author":"Ducray","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.tranon.2021.101027_bib0003","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1080\/14737140.2018.1412260","article-title":"Targeted therapies in non-small cell lung cancer: a focus on ALK\/ROS1 tyrosine kinase inhibitors","volume":"18","author":"Sgambato","year":"2018","journal-title":"Expert Rev Anticancer Ther"},{"issue":"8","key":"10.1016\/j.tranon.2021.101027_bib0004","doi-asserted-by":"crossref","first-page":"141","DOI":"10.21037\/atm.2017.11.34","article-title":"Treating ALK-positive non-small cell lung cancer","volume":"6","author":"Ziogas","year":"2018","journal-title":"Ann Transl Med"},{"issue":"1","key":"10.1016\/j.tranon.2021.101027_bib0005","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s12943-018-0810-4","article-title":"The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC)","volume":"17","author":"Golding","year":"2018","journal-title":"Mol Cancer"},{"issue":"12","key":"10.1016\/j.tranon.2021.101027_bib0006","doi-asserted-by":"crossref","first-page":"e202","DOI":"10.1016\/j.jtho.2017.08.009","article-title":"Case report of non-small cell lung cancer with STRN-ALK translocation: a nonresponder to alectinib","volume":"12","author":"Nakanishi","year":"2017","journal-title":"J Thorac Oncol"},{"issue":"11","key":"10.1016\/j.tranon.2021.101027_bib0007","doi-asserted-by":"crossref","first-page":"4233","DOI":"10.1073\/pnas.1321937111","article-title":"Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer","volume":"111","author":"Kelly","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.tranon.2021.101027_bib0008","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1001\/jamaoncol.2017.2918","article-title":"Identification of ALK rearrangements in malignant peritoneal mesothelioma","volume":"4","author":"Hung","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.tranon.2021.101027_bib0009","article-title":"Salivary intraductal carcinoma arising within intraparotid lymph node: a report of 4 cases with identification of a novel STRN-ALK fusion","author":"Rooper","year":"2020","journal-title":"Head Neck Pathol"},{"issue":"1","key":"10.1016\/j.tranon.2021.101027_bib0010","doi-asserted-by":"crossref","first-page":"e87170","DOI":"10.1371\/journal.pone.0087170","article-title":"Identification of a recurrent STRN\/ALK fusion in thyroid carcinomas","volume":"9","author":"Perot","year":"2014","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.tranon.2021.101027_bib0011","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.19.00048","article-title":"STRN-ALK rearranged malignant peritoneal mesothelioma with dramatic response following ceritinib treatment","author":"R\u00fcschoff","year":"2019","journal-title":"JCO Precision Oncology"},{"issue":"11","key":"10.1016\/j.tranon.2021.101027_bib0012","doi-asserted-by":"crossref","first-page":"236","DOI":"10.21037\/atm.2017.03.96","article-title":"Malignant peritoneal mesothelioma: a review","volume":"5","author":"Kim","year":"2017","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.tranon.2021.101027_bib0013","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.3389\/fonc.2019.01519","article-title":"Malignant pleural mesothelioma: state-of-the-art on current therapies and promises for the future","volume":"9","author":"Nicolini","year":"2019","journal-title":"Front Oncol"},{"issue":"9","key":"10.1016\/j.tranon.2021.101027_bib0014","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/nm.4389","article-title":"Functional precision cancer medicine-moving beyond pure genomics","volume":"23","author":"Letai","year":"2017","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.tranon.2021.101027_bib0015","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1158\/2159-8290.CD-13-0350","article-title":"Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia","volume":"3","author":"Pemovska","year":"2013","journal-title":"Cancer Discov"},{"key":"10.1016\/j.tranon.2021.101027_bib0016","doi-asserted-by":"crossref","first-page":"5193","DOI":"10.1038\/srep05193","article-title":"Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies","volume":"4","author":"Yadav","year":"2014","journal-title":"Sci Rep"},{"issue":"11","key":"10.1016\/j.tranon.2021.101027_bib0017","doi-asserted-by":"crossref","first-page":"3602","DOI":"10.1093\/bioinformatics\/btaa138","article-title":"Breeze: an integrated quality control and data analysis application for high-throughput drug screening","volume":"36","author":"Potdar","year":"2020","journal-title":"Bioinformatics"},{"issue":"15","key":"10.1016\/j.tranon.2021.101027_bib0018","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1093\/bioinformatics\/btx162","article-title":"SynergyFinder: a web application for analyzing drug combination dose-response matrix data","volume":"33","author":"Ianevski","year":"2017","journal-title":"Bioinformatics"},{"issue":"12","key":"10.1016\/j.tranon.2021.101027_bib0019","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.5858\/arpa.2014-0061-RA","article-title":"Immunohistochemistry in undifferentiated neoplasm\/tumor of uncertain origin","volume":"138","author":"Lin","year":"2014","journal-title":"Arch Pathol Lab Med"},{"issue":"1","key":"10.1016\/j.tranon.2021.101027_bib0020","doi-asserted-by":"crossref","first-page":"334","DOI":"10.2353\/ajpath.2009.081030","article-title":"Prognostic significance of stromal platelet-derived growth factor beta-receptor expression in human breast cancer","volume":"175","author":"Paulsson","year":"2009","journal-title":"Am J Pathol"},{"issue":"6216","key":"10.1016\/j.tranon.2021.101027_bib0021","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1126\/science.1254721","article-title":"Patient-derived models of acquired resistance can identify effective drug combinations for cancer","volume":"346","author":"Crystal","year":"2014","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.tranon.2021.101027_bib0022","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1093\/bioinformatics\/btaa102","article-title":"SynergyFinder: a web application for analyzing drug combination dose-response matrix data","volume":"36","author":"Ianevski","year":"2020","journal-title":"Bioinformatics"},{"issue":"4","key":"10.1016\/j.tranon.2021.101027_bib0023","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/his.12779","article-title":"Anaplastic lymphoma kinase (ALK) translocation in paediatric malignant peritoneal mesothelioma: a case report of novel ALK-related tumour spectrum","volume":"68","author":"Loharamtaweethong","year":"2016","journal-title":"Histopathology"},{"issue":"2","key":"10.1016\/j.tranon.2021.101027_bib0024","doi-asserted-by":"crossref","first-page":"e142","DOI":"10.1016\/j.cllc.2018.11.002","article-title":"Identification and development of a lung adenocarcinoma PDX model with STRN-ALK fusion","volume":"20","author":"Ren","year":"2019","journal-title":"Clin Lung Cancer"},{"issue":"1","key":"10.1016\/j.tranon.2021.101027_bib0025","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.mayocpiqo.2017.04.003","article-title":"A Rare STRN-ALK fusion in lung adenocarcinoma identified using next-generation sequencing-based circulating tumor DNA profiling exhibits excellent response to crizotinib","volume":"1","author":"Yang","year":"2017","journal-title":"Mayo Clin Proc Innov Qual Outcomes"},{"issue":"6","key":"10.1016\/j.tranon.2021.101027_bib0026","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1097\/PAS.0000000000000610","article-title":"Two cases of renal cell carcinoma harboring a novel STRN-ALK fusion gene","volume":"40","author":"Kusano","year":"2016","journal-title":"Am J Surg Pathol"},{"issue":"11","key":"10.1016\/j.tranon.2021.101027_bib0027","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1158\/1541-7786.MCR-18-0171","article-title":"ALK fusion partners impact response to ALK inhibition: differential effects on sensitivity, cellular phenotypes, and biochemical properties","volume":"16","author":"Childress","year":"2018","journal-title":"Mol Cancer Res"},{"issue":"2","key":"10.1016\/j.tranon.2021.101027_bib0028","first-page":"156","article-title":"Ceritinib for ALK-rearrangement-positive non-small cell lung cancer","volume":"6","author":"Nix","year":"2015","journal-title":"J Adv Pract Oncol"},{"issue":"26","key":"10.1016\/j.tranon.2021.101027_bib0029","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1056\/NEJMc1404894","article-title":"Ceritinib in ALK-rearranged non-small-cell lung cancer","volume":"370","author":"Shaw","year":"2014","journal-title":"N Engl J Med"},{"issue":"10089","key":"10.1016\/j.tranon.2021.101027_bib0030","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(17)30565-2","article-title":"Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial","volume":"390","author":"Hida","year":"2017","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.tranon.2021.101027_bib0031","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1056\/NEJMoa1810171","article-title":"Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer","volume":"379","author":"Camidge","year":"2018","journal-title":"N Engl J Med"},{"issue":"34","key":"10.1016\/j.tranon.2021.101027_bib0032","doi-asserted-by":"crossref","first-page":"56338","DOI":"10.18632\/oncotarget.17630","article-title":"Identification of precision treatment strategies for relapsed\/refractory multiple myeloma by functional drug sensitivity testing","volume":"8","author":"Majumder","year":"2017","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.tranon.2021.101027_bib0033","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.eururo.2016.04.019","article-title":"Comprehensive drug testing of patient-derived conditionally reprogrammed cells from castration-resistant prostate cancer","volume":"71","author":"Saeed","year":"2017","journal-title":"Eur Urol"},{"issue":"11","key":"10.1016\/j.tranon.2021.101027_bib0034","doi-asserted-by":"crossref","first-page":"3298","DOI":"10.1016\/j.celrep.2017.11.051","article-title":"Primary patient-derived cancer cells and their potential for personalized cancer patient care","volume":"21","author":"Kodack","year":"2017","journal-title":"Cell Rep"}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S193652332100019X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S193652332100019X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T14:40:15Z","timestamp":1761835215000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S193652332100019X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S193652332100019X"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2021.101027","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"STRN-ALK rearranged pediatric malignant peritoneal mesothelioma \u2013 Functional testing of 527 cancer drugs in patient-derived cancer cells","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2021.101027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101027"}}